Intrinsa,Estratest, LibiGel & Flibanserin are some of the few patches and pills that offer to enhance libido in women.
There are many, though, who question the effectiveness of treatments to boost female sex drive. They maintain that the female sex drive is primarily psychological – a documentary recently made named “Orgasm Inc.‘ talked about Big Phrma’s attempts to create a successful drug for treating flagging female libido.
The US FDA defines four components that contribute female sexual dysfunction (FSD) or the reduced sexual desire in women. They are decreased desire, decreased arousal, sexual pain, and orgasm difficulties.
The Journal of the American Medical Association found that 43 percent of American women ages 18 to 59 were sexually dysfunctional, compared with only 31 percent of men. Women’s bodies produce testosterone in small amounts.
Testosterone has always been a leading candidate for sexual therapy because for some women, it works. Prescription data show that several million of them order customized testosterone compounds from pharmacies or use men’s testosterone therapies in lower doses.
The success of male erectile dysfunction drugs like Viagra spurred the pharmaceutical industry on its track to find an equivalent drug to boost female sex drive.
Intrinsa patch is used for sexual arousal in women. The intrinsa patch is a prescription treatment that is placed on the stomach. Testosterone is the main ingredient in an Intrinsa patch. The Intrinsa skin patch supplies low dose of testosterone, a naturally occurring sex hormone in men and women, through the skin into the bloodstream to make up for its lowered level in the body.
Intrinsa testosterone patches are manufactured by Proctor & Gamble. Studies carried out to test the efficacy of these patches have shown positive results of increase in sex drive among women.
Most of the women using intrinsa patches have experienced higher libido, satisfying sexual activity and low associated distress. However, testosterone patches should not be used by women without taking a medical consultation in the UK or elsewhere.
Intrinsa patches are available in packs of 2, 8, and 24. As per the manufacturer’s specifications, you should apply a patch on a fresh skin section of your abdomen once every 24 hours.
The usage of Intrinsa patch may also cause some side effects. These side effects may vary for different women. The most common side effects are rash, irritation, itching, and redness around the area of application. These are generally mild and go away easily after a few days. However, some women may also experience rare side effects such as hair loss, acne, migraine, insomnia, hair growth on the chin or upper lip, pain in breasts, and weight gain.
Another testosteron drug to boost female sex drive is Estratest, manufactured by Solvay Pharmaceuticals. Estratest contains 1.25 mg of esterified estrogens and 2.5 mg of methyltestosterone.
Estratest is available in half-strength formulation – Estratest H.S. (Half-Strength), as well.
The most commonly reported adverse aide effects of using Estrat to boost the female libido are those typical of estrogen therapy such as breast tenderness, headache, nausea, edema and abdominal pain and of androgen treatment including baldness, pimples, and hair growth.
LibiGel is a testesterone gel to enhance female sex drive, being developed by BioSante Pharmaceuticals.
LibiGel is a testosterone patch in the form of gel (not what I say – that’s what the official information from the company says) designed to be quickly absorbed through the skin. It delivers testosterone to the bloodstream evenly over time in a painless manner.
LibiGel’s safety and efficacy have been accepted by US FDA. Currently, BioSante is conducting a safety study of LibiGel.
BioSante expects to be able to file the LibiGel NDA in 2010 for a potential approval and launch in 2011. LibiGel, if approved for use, is expected to cost $4 a day.
Flibanserin, on the other hand, is a potential oral tablet for women with low sexual desire. Flibanserin is currently under development by the German firm Boehringer Ingelheim. The company has conducted studies in North America and Europe involving over 5,000 pre-menopausal women. Flibanserin is a non-hormonal compound.